References
- Dally P J. Indications for use of iproniazid in psychiatric practice. British Medical Journal 1958; 1: 1338–1339
- West E D, Dally P J. Effects of iproniazid in depressive syndromes. British Medical Journal 1959; 1: 1491–1494
- Furst W. Therapeutic reorientation in some depressive states: clinical evaluation of a new MAOI (W-1544-A) (Phenelzine (Nardil)). American Journal of Psychiatry 1959; 116: 429–33
- Alexander L, Berkeley A W. The inert psychasthenic reaction (anhedonia) as differentiated from classical depression and its response to iproniazid. Annals of the New York Academy of Science 1959; 80: 669–677
- Sarwer-Foner G J, Koranyi E K, Meszaros A, Grauer H. Depressive states and drugs: II The study of phenelzine dihydrogen sulphate (Nardil) in open psychiatric settings. Canadian Medical Journal 1959; 81: 991–996
- Kiloh L G, Child J P, Latner G A. Controlled trial of iproniazid in the treatment of endogenous depression. Journal of Mental Science 1960; 106: 1139–1144
- Sargant W. Some newer drugs in the treatment of depression and their relation to other treatments. Psychosomatics 1960; i: 14–17
- Blackwell B. Hypertensive crises due to monoamine oxidase inhibitors. Lancet 1963; ii: 849–851
- Medical Research Council. Clinical trial of the treatment of depressive illness. British Medical Journal 1965; i: 881–886
- Pare C MB. The present status of monoamine oxidase inhibitors. British Journal of Psychiatry 1985; 146: 576–584
- Callingham B A, Ovens R S. Some in vitro effects of moclobemide and other MAO inhibitors on response to sympathomimetic amines. Journal of Neural Transmission 1988; 26: 17–29
- Da Prada M, Keller H, Kettler H., Schaffner R. R, Pieri M, Burkard W P, Korn A, Haefely W E. ROI1–1163, a specific and short-acting MAO inhibitor with antidepressant properties. Monoamine oxidase, basic and clinical frontiers, K Kamijo, E Usdin, T Nagatsu. Excerpta Medica, Amsterdam 1982; 564: 183–196, (International Congress Series)
- Da Prada M, Kettler R, Keller H, Haefely H. WE. Neurochemical effects in vitro of the antidepressant RO11 -1163, a specific and short-acting MAO-A inhibitor. Modern Problems in Pharmacopsychiatry 1983; 19: 231–245
- Keller H H, Kettler R, Keller G, Da Prada M. Short-acting novel MAO inhibitors: in vitro evidence for the reversibility of MAO inhibition by moclobemide and RO 16- 6491. Naunyn-Schmiedeberg's Archives of Pharmacology 1987; 335: 12–20
- Nutt D, Glue P. Monoamine oxidase inhibitors; rehabilitation from recent research. British Journal of Psychiatry 1989; 154: 287–291
- Gieschke R. Schmid-Burgk W, Amrein R. Interaction of moclobemide, a new reversible monoamine oxidase inhibitor with oral tyramine. Journal of Neural Transmission 1988; 26: 97–104
- Korn A, Da Prada M, Raffesberg W, Allen S, Gasic S. Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor. Journal of Neural Transmission 1988; 26: 57–71, [suppl]
- Hamilton M. A rating scale for depression. Neurology, Neurosurgery and Psychiatry 1960; 23: 56–62